Table 1 Patient demographics/baseline characteristics
Placebo (n = 145) | Quilizumab 150 mg Q (n = 145) | Quilizumab 450 mg Q (n = 145) | Quilizumab 300 mg M (n = 143) | All Patients (N = 578) | |
|---|---|---|---|---|---|
Age (y) | 47.9 (13.0) | 46.8 (13.3) | 47.0 (13.6) | 44.8a (12.2) | 46.6 (13.1) |
Gender (Female) | 84 (58 %) | 89 (61 %) | 98 (68 %) | 86 (60 %) | 357 (62 %) |
Race (White) | 122 (84 %) | 119 (82 %) | 117 (81 %) | 114 (80 %) | 472 (82 %) |
Weight (kg) | 82.8 (23.3) | 81.4 (18.13) | 80.3 (21.4) | 81.3 (19.4) | 81.4 (20.6) |
Previous number of exacerbations | |||||
1 | 90 (62 %) | 88 (61 %) | 91 (63 %) | 89 (62 %) | 358 (62 %) |
2 | 30 (21 %) | 33 (23 %) | 31 (21 %) | 28 (20 %) | 122 (21 %) |
≥3 | 25 (17 %) | 24 (17 %) | 23 (16 %) | 26 (18 %) | 98 (17 %) |
FEV1 % predicted | 60.8 (11.9) | 58.6 (12.2) | 61.2 (12.8) | 63 (12.7) | 60.9 (12.5) |
FEV1 % reversibility | 19.6 (15.8) | 23.3 (20.6) | 21.6 (18.8) | 23.4 (18.0) | 22 (18.4) |
IgE (IU/mL) median | 234.0 | 254.0 | 249.5 | 190.0a | 232.5 |
Periostin (ng/mL) median | 51.0 | 53.4 | 52.4 | 52.1 | 51.9 |
FeNO (ppb) | 33.4 (32.0) | 35.7 (36.26) | 33.8 (32.1) | 35.2 (32.5) | 34.5 (33.2) |
Eosinophils (cells/μl) median | 210 | 220 | 220 | 240 | 220 |